C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter A—GeneralPart 10—Administrative Practices and ProceduresSubpart B—General Administrative Procedures

21 C.F.R. § 10.45 (2026)

Court review of final administrative action; exhaustion of administrative remedies

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1980–2026 41citing cases
At a glance

Courts have cited this section in 41 opinions since 1980, 7 of them in the last five years. The most litigated part is subsection (b) (1 case).

(a) This section applies to court review of final administrative action taken by the Commissioner, including action taken under §§ 10.25 through 10.40 and § 16.1(b), except action subject to § 10.50 and part 12.

(b) A request that the Commissioner take or refrain from taking any form of administrative action must first be the subject of a final administrative decision based on a petition submitted under § 10.25(a) or, where applicable, a hearing under § 16.1(b) before any legal action is filed in a court complaining of the action or failure to act. If a court action is filed complaining of the action or failure to act before the submission of the decision on a petition under § 10.25(a) or, where applicable, a hearing under § 16.1(b), the Commissioner shall request dismissal of the court action or referral to the agency for an initial administrative determination on the grounds of a failure to exhaust administrative remedies, the lack of final agency action as required by 5 U.S.C. 701 et seq., and the lack of an actual controversy as required by 28 U.S.C. 2201.

(c) A request that administrative action be stayed must first be the subject of an administrative decision based upon a petition for stay of action submitted under § 10.35 before a request is made that a court stay the action. If a court action is filed requesting a stay of administrative action before the Commissioner's decision on a petition submitted in a timely manner pursuant to § 10.35, the Commissioner shall request dismissal of the court action or referral to the agency for an initial determination on the grounds of a failure to exhaust administrative remedies, the lack of final agency action as required by 5 U.S.C. 701 et seq., and the lack of an actual controversy as required by 28 U.S.C. 2201. If a court action is filed requesting a stay of administrative action after a petition for a stay of action is denied because it was submitted after expiration of the time period provided under § 10.35, or after the time for submitting such a petition has expired, the Commissioner will request dismissal of the court action on the ground of a failure to exhaust administrative remedies.

(d) Unless otherwise provided, the Commissioner's final decision constitutes final agency action (reviewable in the courts under 5 U.S.C. 701 et seq. and, where appropriate, 28 U.S.C. 2201) on a petition submitted under § 10.25(a), on a petition for reconsideration submitted under § 10.33, on a petition for stay of action submitted under § 10.35, on an advisory opinion issued under § 10.85, on a matter involving administrative action which is the subject of an opportunity for a hearing under § 16.1(b) of this chapter, or on the issuance of a final regulation published in accordance with § 10.40, except that the agency's response to a petition filed under section 505(j)(2)(C) of the act (21 U.S.C. 355(j)(2)(C)) and § 314.93 of this chapter will not constitute final agency action until any petition for reconsideration submitted by the petitioner is acted on by the Commissioner.

(1) It is the position of FDA except as otherwise provided in paragraph (d)(2) of this section, that:

(i) Final agency action exhausts all administrative remedies and is ripe for preenforcement judicial review as of the date of the final decision, unless applicable law explicitly requires that the petitioner take further action before judicial review is available;

(ii) An interested person is affected by, and thus has standing to obtain judicial review of final agency action; and

(iii) It is not appropriate to move to dismiss a suit for preenforcement judicial review of final agency action on the ground that indispenable parties are not joined or that it is an unconsented suit against the United States if the defect could be cured by amending the complaint.

(2) The Commissioner shall object to judicial review of a matter if:

(i) The matter is committed by law to the discretion of the Commissioner, e.g., a decision to recommend or not to recommend civil or criminal enforcement action under sections 302, 303, and 304 of the act; or

(ii) Review is not sought in a proper court.

(e) An interested person may request judicial review of a final decision of the Commissioner in the courts without first petitioning the Commissioner for reconsideration or for a stay of action, except that in accordance with paragraph (c) of this section, the person shall request a stay by the Commissioner under § 10.35 before requesting a stay by the court.

(f) The Commissioner shall take the position in an action for judicial review under 5 U.S.C. 701 et seq., whether or not it includes a request for a declaratory judgment under 28 U.S.C. 2201, or in any other case in which the validity of administrative action is properly challenged, that the validity of the action must be determined solely on the basis of the administrative record specified in §§ 10.30(i), 10.33(k), 10.35(h), 10.40(g), and 16.80(a) or the administrative record applicable to any decision or action under the regulations referenced in § 16.1(b), and that additional information or views may not be considered. An interested person who wishes to rely upon information or views not included in the administrative record shall submit them to the Commissioner with a new petition to modify the action under § 10.25(a).

(g) The Commissioner requests that all petitions for judicial review of a particular matter be filed in a single U.S. District court. If petitions are filed in more than one jurisdiction, the Commissioner will take appropriate action to prevent a multiplicity of suits in various jurisdictions, such as:

(1) A request for transfer of one or more suits to consolidate separate actions, under 28 U.S.C. 1404(a) or 28 U.S.C. 2112(a);

(2) A request that actions in all but one jurisdiction be stayed pending the conclusion of one proceeding;

(3) A request that all but one action be dismissed pending the conclusion of one proceeding, with the suggestion that the other plaintiffs intervene in that one suit; or

(4) A request that one of the suits be maintained as a class action in behalf of all affected persons.

(h)(1) For the purpose of 28 U.S.C. 2112(a), a copy of any petition filed in any U.S. Court of Appeals challenging a final action of the Commissioner shall be sent by certified mail, return receipt requested, or by personal delivery to the Chief Counsel of FDA. The petition copy shall be time-stamped by the clerk of the court when the original is filed with the court. The petition copy should be addressed to: Office of the Chief Counsel (GCF-1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857. The Chief Counsel requests that the purpose of all petitions mailed or delivered to the Office of Chief Counsel to satisfy 28 U.S.C. 2112(a) be clearly identified in a cover letter.

(2) If the Chief Counsel receives two or more petitions filed in two or more U.S. Courts of Appeals for review of any agency action within 10 days of the effective date of that action for the purpose of judicial review, the Chief Counsel will notify the U.S. Judicial Panel on Multidistrict Litigation of any petitions that were received within the 10-day period, in accordance with the applicable rule of the panel.

(3) For the purpose of determining whether a petition for review has been received within the 10-day period under paragraph (h)(2) of this section, the petition shall be considered to be received on the date of delivery, if personally delivered. If the delivery is accomplished by mail, the date of receipt shall be the date noted on the return receipt card.

(i) Upon judicial review of administrative action under this section:

(1) If a court determines that the administrative record is inadequate to support the action, the Commissioner shall determine whether to proceed with such action. (i) If the Commissioner decides to proceed with the action, the court will be requested to remand the matter to the agency to reopen the administrative proceeding and record, or on the Commissioner's own initiative the administrative proceeding and record may be reopened upon receipt of the court determination. A reopened administrative proceeding will be conducted under the provisions of this part and in accordance with any directions of the court.

(ii) If the Commissioner concludes that the public interest requires that the action remain in effect pending further administrative proceedings, the court will be requested not to stay the matter in the interim and the Commissioner shall expedite the further administrative proceedings.

(2) If a court determines that the administrative record is adequate, but the rationale for the action must be further explained:

(i) The Commissioner shall request either that further explanation be provided in writing directly to the court without further administrative proceedings, or that the administrative proceeding be reopened in accordance with paragraph (i)(1)(i) of this section; and

(ii) If the Commissioner concludes that the public interest requires that the action remain in effect pending further court or administrative proceedings, the court will be requested not to stay the matter in the interim and the Commissioner shall expedite the further proceedings.

[44 FR 22323, Apr. 13, 1979, as amended at 54 FR 6886, Feb. 15, 1989; 54 FR 9034, Mar. 3, 1989; 57 FR 17980, Apr. 28, 1992; 65 FR 56477, Sept. 19, 2000; 69 FR 31705, June 4, 2004]
The 20 cases that cite 21 C.F.R. § 10.45 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENHeckler v. Chaney, 470 U.S. 821 (1985).
cites § 10.45 2×cited by 2,449 cases
Where it cites § 10.45
“In addition, if read to circumscribe agency enforcement discretion, the statement conflicts with the agency rule on judicial review, 21 CFR § 10.45 (d)(2) (1984), which states that "[t]he Commissioner shall object to judicial review .”
The case’s holding
An agency decision not to enforce is generally committed to its absolute discretion and is unreviewable unless the governing statute provides meaningful standards for judicial review.
Later courts cite it for
“review is not to be had if the statute is drawn so that a court would have no meaningful standard against which to judge the agency's exercise of discretion.” · 362 citing courts
2
REDAll. Hippocratic Med. v. FDA, 78 F.4th 210 (5th Cir. 2023).
cites § 10.45 3×cited by 24 cases
Reversed by FDA v. Alliance for Hippocratic Medicine (2024): the U.S. Supreme Court's own opinion in this case.
Where it cites § 10.45
“See 21 C.F.R. § 10.45 (c) (“A request that administrative action be stayed must first be the subject of an administrative decision based upon a petition for stay of action .”
The case’s holding
An associational standing claim requires demonstrating a substantial risk of future injury to members through predictable and consistent agency policies.
Later courts cite it for
“all of this violates the comstock act.” · 3 citing courts
3
GREENStega v. New York Downtown Hosp., 107 N.E.3d 543 (N.Y. 2018).
cites § 10.45 2×cited by 30 cases
Where it cites § 10.45
“121 [a]) and subsequent judicial review ( see 21 CFR 10.45), qualify as a quasi-judicial process by an administrative agency" ( 148 AD3d at 28 ).”
The case’s holding
Absolute privilege in a quasi-judicial context requires a mechanism for the party to challenge the allegedly defamatory statements within the proceeding.
Later courts cite it for
“statements uttered in the course of a judicial proceeding are absolutely privileged, 'as long as such statements are material and pertinent to the questions involved' in the proceeding” · 4 citing courts
4
REDStega v. New York Downtown Hosp., 148 A.D.3d 21 (N.Y. App. Div. 1st Dep't 2017).
cites § 10.45 6×cited by 3 cases
Reversed by Stega v. New York Downtown Hosp. (2018): the New York Court of Appeals's own opinion in this case.
Where it cites § 10.45
“If it is determined that the IRB or the institution has failed to take adequate steps to correct the noncompliance, and the FDA Commissioner determines that this noncompliance may justify the disqualification of the IRB or of the parent institution, "the Commissioner will…”
5
GREENBiovail Corp. v. U.S. Food & Drug Admin., 448 F. Supp. 2d 154 (D.D.C. 2006).
cites § 10.45 2×subsections: (d) 2×cited by 19 cases
Where it cites § 10.45
“21 C.F.R. 10.45(d). The plaintiff does not claim that these two occasions to be heard are inadequate process.”
Later courts cite it for
“in receiving generic competition to brand-name drugs as soon as is possible” · 2 citing courts
6
GREENSchering Corp. v. Food & Drug Admin., 51 F.3d 390 (3d Cir. 1995).
cites § 10.45 2×cited by 44 cases
Where it cites § 10.45
“See 21 C.F.R. § 10.45 (d) (1990). Schering thus sought review of the FDA’s response to its Citizen Petition in the United States District Court for the District of Columbia.”
The case’s holding
A potential loss of monopoly profits resulting from the approval of a generic substitute constitutes a sufficient injury in fact to establish Article III standing.
Later courts cite it for
“judgments as to what is required to ascertain the safety and efficacy of drugs falls squarely within the ambit of the fda's expertise and merit deference from us.” · 4 citing courts
7
GREENIndep. Turtle Farmers of Louisiana, Inc. v. United States, 703 F. Supp. 2d 604 (W.D. La. 2010).
cites § 10.45 2×cited by 10 cases
Where it cites § 10.45
“” 21 C.F.R. § 10.45 (d). Therefore, the Court has jurisdiction to review the FDA’s action.”
8
GREENAss'n of Am. Physicians & Surgeons v. Food & Drug Admin., 539 F. Supp. 2d 4 (D.D.C. 2008).
cites § 10.45 1×cited by 22 cases
Where it cites § 10.45
“45(e) states that: “An interested person may request judicial review of a final decision of the Commissioner in the courts without first petitioning the Commissioner for reconsideration or for a stay of action, except that in accordance with paragraph (c) of this section, the…”
9
GREENJHP Pharm., LLC v. Hospira, Inc., 52 F. Supp. 3d 992 (C.D. Cal. 2014).
cites § 10.45 1×cited by 19 cases
Where it cites § 10.45
“” Were Par’s claim that the FDA had acted unlawfully, or that the FDA had failed to act where it was required to do so, exhaustion would come into play.”
The case’s holding
Lanham Act false-advertising claims are generally not precluded by the FDCA, and whether a product is FDA-approved is a simple factual question that need not be referred to the FDA.
Later courts cite it for
“make determinations within the exclusive purview of fda authority.” · 2 citing courts
10
GREENHolistic Candlers & Consum. Ass'n v. U.S. Food & Drug Admin., 770 F. Supp. 2d 156 (D.D.C. 2011).
cites § 10.45 2×cited by 6 cases
Where it cites § 10.45
“” 21 C.F.R. § 10.45 (b). Unfortunately, plaintiffs have not initiated the administrative-review process, let alone exhausted their administrative remedies.”
Later courts cite it for
“but, an agency action is 'final for the purposes of the apa' only after a plaintiff has exhausted all administrative remedies expressly prescribed by statute or agency rule.” · 2 citing courts
11
GREENPfizer Inc v. Shalala, Donna E., 182 F.3d 975 (D.C. Cir. 1999).
cites § 10.45 1×cited by 42 cases
Where it cites § 10.45
“renewable in the courts,” 21 C.F.R. § 10.45 (d); but a final agency action nonetheless can be unripe for judicial review.”
The case’s holding
To determine ripeness, a court must evaluate both the fitness of the issues for judicial decision and the hardship to the parties of withholding court consideration.
Later courts cite it for
“in order to determine whether a controversy is ripe, a court must 'evaluate both the fitness of the issues for judicial decision and the hardship to the parties of withholding court consideration.” · 3 citing courts
12
GREENTummino v. Torti, 603 F. Supp. 2d 519 (E.D.N.Y. 2009).
cites § 10.45 1×cited by 15 cases
Where it cites § 10.45
“Hayes, 818 F.2d 879 , 887 n. 61 (D.C.Cir.1987). Moreover, FDA regulations make clear that petitions for judicial review of a citizen petition may be filed in district court.”
The case’s holding
An agency decision is arbitrary and capricious under the Administrative Procedure Act if it results from political interference, bad faith, or departures from normal procedures without reasoned explanation.
Later courts cite it for
“trusted to conduct a fair assessment of the scientific evidence.” · 2 citing courts
13
GREENMylan Pharm., Inc. v. Henney, 94 F. Supp. 2d 36 (D.D.C. 2000).
cites § 10.45 1×cited by 27 cases
Where it cites § 10.45
“Thus, the FDA’s March Letter constitutes final agency action. 3. Mylan’s Claims of Entitlement to Exclusivity are Not the Proper Subject of Review Because Mylan Has Failed to Exhaust its Administrative Remedies The administrative record in this ease includes Barr’s Petition,…”
The case’s holding
Consolidation under Rule 42(a) is proper for any or all common matters in issue, even where the plaintiffs seek different forms of relief.
Later courts cite it for
“the plaintiffs' requests for different forms of relief do not vitiate the propriety of consolidation, but rather, consolidation is proper to any or all matters in issue which are common.” · 2 citing courts
14
REDTeva Pharm. USA, Inc. v. Sebelius, 638 F. Supp. 2d 42 (D.D.C. 2009).
cites § 10.45 1×cited by 10 cases
Reversed by Teva Pharmaceuticals USA, Inc. v. Sebelius (2010): the Court of Appeals for the D.C. Circuit's own opinion in this case.
Where it cites § 10.45
“FDA regulations require that, before filing suit in court, a party requesting that the FDA take or refrain from taking an action must first use the citizen petition process set forth in 21 C.”
15
GREENKing v. Leavitt, 475 F. Supp. 2d 67 (D.D.C. 2007).
cites § 10.45 1×cited by 9 cases
Where it cites § 10.45
“” 21 C.F.R. § 10.45 (b). It is well-established that a party may not seek judicial review of an agency decision while simultaneously asking the agency to reconsider its decision because a “request for administrative reconsideration renders an agency’s otherwise final action…”
cites § 10.45 1×cited by 4 cases
Where it cites § 10.45
“§ 702 ; 21 C.F.R. § 10.45 . While an appeal of the FDA's decision might have resolved the issues, it would not have interfered with the FDA's review of the pending ANDAs, which plaintiffs allege to have been Allergan's true goal.”
17
GREENHill Dermaceuticals, Inc. v. U.S. Food & Drug Admin., 524 F. Supp. 2d 5 (D.D.C. 2007).
cites § 10.45 1×cited by 8 cases
Where it cites § 10.45
“See 21 C.F.R. § 10.45 (providing for an opportunity to appeal denial of citizen petitions).”
Later courts cite it for
“the public interest weighs strongly in favor of preventing unsafe drugs from entering the market.” · 2 citing courts
18
GREENFarm-To-Consum. Legal Def. Fund v. Sebelius, 734 F. Supp. 2d 668 (N.D. Iowa 2010).
cites § 10.45 5×cited by 1 case
Where it cites § 10.45
“The defendants contend that, pursuant to 21 C.F.R. § 10.45 (b), before any legal action is filed in a court, a party must first file a citizen petition to request that the Commissioner take or refrain from taking any form of administrative action and, pursuant to 21 C.”
19
GREENGenendo Pharm. N v. v. Thompson, 308 F. Supp. 2d 881 (N.D. Ill. 2003).
cites § 10.45 1×cited by 7 cases
Where it cites § 10.45
“21 C.F.R. § 10.45 (d). Second, as noted above, Plaintiffs can litigate the legality of their conduct in the seizure action recently filed by the government.”
20
GREENPfizer, Inc. v. Food & Drug Admin., 753 F. Supp. 171 (D. Md. 1990).
cites § 10.45 1×cited by 8 cases
Where it cites § 10.45
“Pfizer claims that the FDA’s decision, which constitutes final agency action under 21 C.F.R. § 10.45 (d), was contrary to law.”

Show all 41 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198020032026

One bar per year. Tallest: 4 cases in 2023. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.124th Cir.33rd Cir.25th Cir.2D.C. Cir.2D. Md.2E.D.N.Y210th Cir.1

The 8 courts with the most citing cases, of 23 courts in all.

By subsection
(b)1 case
Vanda Pharm. Inc. v. Food & Drug Admin., No. 2023-2812 (D.D.C. Sept. 10, 2024).
(d)1 case
Biovail Corp. v. U.S. Food & Drug Admin., 448 F. Supp. 2d 154 (D.D.C. 2006).“21 C.F.R. 10.45(d). The plaintiff does not claim that these two occasions to be heard are inadequate process.”
(d)(1)1 case
Pac. Legal Found. v. Goyan, 664 F.2d 1221 (4th Cir. 1981).
(d)(1)(ii)1 case
Pac. Legal Found. v. Goyan, 664 F.2d 1221 (4th Cir. 1981).

Show all 41 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com